Effects of Carvedilol as Third-Line Add-On Therapy on Blood Pressure and Glucose Metabolism in Type 2 Diabetic Patients with Chronic Renal Disease Stage 3 and Above | Zendy

Gen Yasuda | Zendy; Keisuke Yatsu | Zendy; Yuichiro Yamamoto | Zendy; Nobuhito Hirawa | Zendy

Open Access

Effects of Carvedilol as Third-Line Add-On Therapy on Blood Pressure and Glucose Metabolism in Type 2 Diabetic Patients with Chronic Renal Disease Stage 3 and Above

Author(s) -

Gen Yasuda,

Keisuke Yatsu,

Yuichiro Yamamoto,

Nobuhito Hirawa

Publication year - 2012

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000341491

Subject(s) - carvedilol , medicine , blood pressure , diabetic nephropathy , carbohydrate metabolism , diabetes mellitus , pharmacology , urology , calcium channel blocker , telmisartan , endocrinology , heart failure

We evaluated the effect of coadministration of β-blocker (carvedilol) as the third agent with angiotensin II receptor blockers (ARB) and calcium channel blockers (CCB) on blood pressure (BP) regulation and glucose metabolism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research